Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Apr 26;96(7):1023–1028. doi: 10.1136/bjophthalmol-2012-301677

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

PMC Copyright notice

Vascular endothelial growth factor (VEGF₁₆₅)-stimulated proliferation and migration of immortalised bovine retinal endothelial cells (iBREC) is inhibited by bevacizumab. (A) Serum-starved iBREC were incubated with VEGF₁₆₅ in the presence or absence of bevacizumab and their proliferation was measured after 24 h. (B) iBREC migration towards fibronectin was measured in a modified Boyden-chamber. VEGF₁₆₅-stimulated migration was inhibited by bevacizumab below the level of basal migration.